Researchers have been studying cannabis therapy for a number of years at international research centers around the globe. Studies involve determining the effects, risks as well as potential future applications.
Raphael Mechoulam published his findings in the newest issue of the Journal of Basic and Clinical Physiology and Pharmacology (or JBCPP). His research projects and clinical trials at Israeli Universities and hospitals have focused on the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD). He has found evidence that cannabinoids are very beneficial in the treatment of a wide range of serious conditions, including Parkinson’s disease and epilepsy. Mechoulam plans to focus on more extensive clinical trials to further the knowledge of these substances and find more wide range applications.
Canadian researcher Mary E. Lynch says 25 out of 30 controlled trials have shown cannabinoids to offer pain relief. These findings are extremely important as there are more people living longer than ever before and with old age, comes more need for pain remedies.
Many other articles were published in the journal that cover a wide range of topics surrounding the use of cannabis, including treatment of anxiety disorders, kidney disease, glaucoma and even traumatic brain injury. Germany has begun to greatly debate cannabis as a treatment resource for many ailments due to the recent legalization of cannabis in the United States for medical purposes. Legislators there have recently passed laws (which will go into effect in spring of 2017) that will allow patients who are extremely ill to use dried cannabis flowers and even cannabis extracts. A prescription will be required from a doctor and patients will only qualify if there are not currently any form of alternative treatments available to the patients.
More and more physicians and pharmacologists are jumping on the band wagon for additional clinical research when it comes to using cannabis on a medical level. Many professionals find such treatment provides a large number of benefits within very minimal risk.